NO922990L - Forbedret cyklodekstrinbasert erytropoietinformulering - Google Patents

Forbedret cyklodekstrinbasert erytropoietinformulering

Info

Publication number
NO922990L
NO922990L NO92922990A NO922990A NO922990L NO 922990 L NO922990 L NO 922990L NO 92922990 A NO92922990 A NO 92922990A NO 922990 A NO922990 A NO 922990A NO 922990 L NO922990 L NO 922990L
Authority
NO
Norway
Prior art keywords
erytropoiet
cyclode
extra
improved
information
Prior art date
Application number
NO92922990A
Other languages
English (en)
Other versions
NO304728B1 (no
NO922990D0 (no
Inventor
Frank Jozef Konings
Marcus Joannes Maria Noppe
Jean Louis Mesens
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10670074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO922990(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO922990L publication Critical patent/NO922990L/no
Publication of NO922990D0 publication Critical patent/NO922990D0/no
Publication of NO304728B1 publication Critical patent/NO304728B1/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO922990A 1990-01-29 1992-07-29 Fremgangsmaate for fremstilling av et cyklodekstrinbasert erytropoietinprepat NO304728B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909001987A GB9001987D0 (en) 1990-01-29 1990-01-29 Improved cyclodextrin based erythropietin formulation
PCT/EP1991/000173 WO1991011200A1 (en) 1990-01-29 1991-01-25 Improved cyclodextrin based erythropoietin formulation

Publications (3)

Publication Number Publication Date
NO922990L true NO922990L (no) 1992-07-29
NO922990D0 NO922990D0 (no) 1992-07-29
NO304728B1 NO304728B1 (no) 1999-02-08

Family

ID=10670074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922990A NO304728B1 (no) 1990-01-29 1992-07-29 Fremgangsmaate for fremstilling av et cyklodekstrinbasert erytropoietinprepat

Country Status (20)

Country Link
US (1) US5376632A (no)
EP (1) EP0513072B1 (no)
JP (1) JP2997052B2 (no)
KR (1) KR0183445B1 (no)
AT (1) ATE107518T1 (no)
AU (1) AU648061B2 (no)
CA (1) CA2074820C (no)
DE (1) DE69102627T2 (no)
DK (1) DK0513072T3 (no)
ES (1) ES2059115T3 (no)
FI (1) FI105012B (no)
GB (1) GB9001987D0 (no)
HU (1) HU218213B (no)
IE (1) IE65209B1 (no)
IL (1) IL97019A (no)
NO (1) NO304728B1 (no)
NZ (1) NZ236938A (no)
PT (1) PT96593B (no)
WO (1) WO1991011200A1 (no)
ZA (1) ZA91620B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
JP2000509374A (ja) 1996-04-19 2000-07-25 アルファ セラピュティック コーポレイション 凍結乾燥した血液タンパク質のウイルス不活性化方法
US5754937A (en) 1996-05-15 1998-05-19 Stackpole Limited Hi-density forming process
CA2284910C (en) * 1997-03-18 2003-01-28 Roche Diagnostics Gmbh Pharmaceutical combined preparations containing erythropoietin and iron preparations
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
CN1165339C (zh) * 1999-04-09 2004-09-08 奥索-麦克尼尔药品公司 红细胞生成素药物组合物
US20040038878A1 (en) * 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
US20060235366A1 (en) * 2000-12-20 2006-10-19 Fox Hollow Technologies, Inc. Method of evaluating a treatment for vascular disease
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
EP1413310A1 (en) * 2001-07-09 2004-04-28 Yamanouchi Pharmaceutical Co. Ltd. Sustained-release compositions for injection and process for producing the same
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
ATE553747T1 (de) 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20110236902A1 (en) * 2004-12-13 2011-09-29 Tyco Healthcare Group Lp Testing a patient population having a cardiovascular condition for drug efficacy
US7794413B2 (en) * 2005-04-19 2010-09-14 Ev3, Inc. Libraries and data structures of materials removed by debulking catheters
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
BRPI0717460A2 (pt) 2006-10-20 2013-12-24 Icos Corp Composições de inibidores de chk1
WO2012003960A1 (en) * 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4920214A (en) * 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
EP0308181A1 (en) * 1987-09-14 1989-03-22 Novo Nordisk A/S Trans-mucosal delivery formulations and a method for preparation thereof
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers

Also Published As

Publication number Publication date
DK0513072T3 (da) 1994-08-01
HU218213B (hu) 2000-06-28
EP0513072A1 (en) 1992-11-19
DE69102627D1 (de) 1994-07-28
FI923402A (fi) 1992-07-28
ES2059115T3 (es) 1994-11-01
WO1991011200A1 (en) 1991-08-08
US5376632A (en) 1994-12-27
IE65209B1 (en) 1995-10-04
CA2074820C (en) 2003-10-14
AU7149791A (en) 1991-08-21
JP2997052B2 (ja) 2000-01-11
EP0513072B1 (en) 1994-06-22
JPH05503700A (ja) 1993-06-17
IL97019A0 (en) 1992-03-29
PT96593B (pt) 2001-06-29
ZA91620B (en) 1992-10-28
CA2074820A1 (en) 1991-07-30
HUT62198A (en) 1993-04-28
HU9202432D0 (en) 1992-10-28
IL97019A (en) 1997-07-13
PT96593A (pt) 1991-10-15
ATE107518T1 (de) 1994-07-15
FI923402A0 (fi) 1992-07-28
NO304728B1 (no) 1999-02-08
IE910286A1 (en) 1991-07-31
DE69102627T2 (de) 1994-11-03
GB9001987D0 (en) 1990-03-28
AU648061B2 (en) 1994-04-14
FI105012B (fi) 2000-05-31
NO922990D0 (no) 1992-07-29
NZ236938A (en) 1992-07-28
KR0183445B1 (en) 1999-05-01

Similar Documents

Publication Publication Date Title
NO922990L (no) Forbedret cyklodekstrinbasert erytropoietinformulering
EP0214647A3 (en) Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
AR021811A1 (es) Compuestos de piridina fusionados, utiles como inhibidores de gmpc fosfodiesterasa y las composiciones farmaceuticas que las contienen.
DK1200418T3 (da) Nematodicide trifluorbutener
DE69428334D1 (de) Wässrige Lösungen enthaltend Inklusionskomplexe aus Benzothiophenderivaten und Cyclodextrinen
DE69625354D1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
ATE132518T1 (de) Hilfstoffzusammensetzungen in fester form dispergierbar in wasserigen medien und verfahren zur herstellung davon
HUT68239A (en) Process for producing inclusion complexes of nimesulide alkali salts with cyclodextrins or cyclodextrin derivatives and pharmaceutical preparations containing them
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
DE69202903T2 (de) Verfahren zur Stabilisierung von Isocyanatderivaten und hierdurch stabilisierte Isocyanatzusammensetzungen.
NO913887D0 (no) Inlusjonskomplekser med silybinin, fremstilling av dem ogfarmasoeytiske preparater inneholdende dem.
NO922682L (no) Polysakkaridblanding, fremgangsmaate for dens fremstillingog anvendelse derav
DE68912809D1 (de) Verfahren zur Herstellung von Bis(2,2,6,6-tetramethyl-4-piperidyl)amin.
IT1208532B (it) Derivati di imminotiazolidina, processo per prepararli e composizioni farmaceutiche che licontengono.
MD679F1 (en) Inclusion complex of N-ethoxycarbonyl-3-morpholinsydnonimine or salts thereof with cyclodextrin or its derivatives, preparation thereof and pharmaceutical compositions containing them, method of preparation thereof and treatment method
DE68923159T2 (de) Verfahren zur Herstellung von 1,4-Dihydropyridin-Derivaten.
DK0457215T3 (da) 3-deamino-4-desoxy-4-amino-8-fluoranthracycliner samt fremgangsmåder til fremstilling deraf
DE69009651T2 (de) Verfahren zur Herstellung von 3,4-Dihydrocumarinderivaten.
DE69215511T2 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
IT1264495B1 (it) Complessi solubili in acqua di glicosaminoglicani, loro procedimento di preparazione e composizioni farmaceutiche che li contengono
YU48230B (sh) Kristalni deoksispergvalin i postupak za njegovo pripremanje